Fig. 3 | Scientific Reports

Fig. 3

From: Complete preclinical evaluation of the novel antibody mimetic Nanofitin-IRDye800CW for diverse non-invasive diagnostic applications in the management of HER-2 positive tumors

Fig. 3

In vivo and ex vivo biodistribution at different time points after administration of NF-800 in BT-474 xenograft tumor bearing mice. (a), In vivo fluorescence signal decay in tumor and muscle and TBR (mean ± SD). Two-way ANOVA, Sidak’s multiple comparisons test (* = p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (b), Ex vivo biodistribution in tumor and main organs. Results are expressed as Average Radiant Efficiency (mean ± SD). (c), Ex vivo tumor and excretory organs (liver and kidney) to background ratio. Two-way ANOVA, Tukey’s multiple comparisons test (* = p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). For each group at least n = 4.

Back to article page